Half Year Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Update on China Grand Pharmaceutical and Healthcare Holdings
- First patient treated in cohort 2 neuroblastoma trial
- US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
- Clarity receives $3.26 million R&D tax incentive refund
- SARTATE Neuroblastoma trial advances to cohort 2
Later from Clarity Pharmaceuticals
- Clarity Half Yearly Report
- First patient treated in the prostate cancer imaging trial
- Presentation Jefferies Biotech Summit
- Notification regarding unquoted securities - CU6
- IND Approval by US FDA for Phase II SAR-Bombesin trial
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals